International private equity group Bridgepoint has acquired a majority stake in HTL, a specialist in the
manufacture, marketing and innovation of hyaluronic acid (HA) and its by-products, from Naxicap. Naxicap will reinvest
via a significant minority interest. Terms of the transaction have not bee...
Télécharger le communiqué au format PDF